NDA 216395 · Solubiomix
Quiofic
Folic Acid · Oral
Last checked: Nov 20, 2026Latest source record: Jan 26, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2026
Jan 26, 2026
Approved uses
1
Original approval plus efficacy supplements
Registered trials
2,128
539 Phase 3, 261 recruiting
FAERS reports
250,981
186,221 serious, 23,615 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 5, 2026.
FOLIC ACID oral solution is indicated for the treatment of megaloblastic anemias due to folic acid deficiency in adult and pediatric patients. FOLIC ACID oral solution is a folate analog indicated for the treatment of megaloblastic anemias due to folic acid deficiency in adult and pediatric patients. ( 1 )
Mechanism: Folic acid acts on megaloblastic bone marrow to produce a normoblastic marrow. In man, an exogenous source of folate is required for nucleoprotein synthesis and the maintenance of normal erythropoiesis. Folic acid is the precursor of tetrahydrofolic acid, which is involved as a cofactor for transformylation reactions in the biosynthesis of purines and thymidylates of nucleic acids. Impairment of thymidylate synthesis in patients with folic acid deficiency is thought to account for the defective deoxyribonucleic acid (DNA) synthesis that leads to megaloblast formation and megaloblastic and...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- QUIOFIC · FOLIC ACID 0.2MG/ML · SOLUTION, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Folic Acid" as an intervention, any sponsor and status, largest first.
- Impact of Zinc Supplementation on Mortality and Hospitalizations in Children Aged 1 Months to 23 MonthsPivotal-lookingCompleted
Society for Applied StudiesAcademic, hospital or other
NCT00269542 · 94,359 participants · Start Feb 2002 · Primary completion Mar 2003
Drug: Zinc and iron folic acid - Intervention; Iron Folic Acid alone - Placebo · For: Morbidity; Mortality; Diarrhea and 1 more
- Community Trial of Zinc Supplementation on Preschool Child Mortality and Morbidity in Southern NepalPivotal-lookingCompleted
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)NIH
NCT00109551 · 58,000 participants · Start Oct 2001
Drug: zinc sulphate dietary supplement; iron sulphate-folic acid dietary supplement · For: Nutrition
Sites: Baltimore, Maryland; Ithaca, New York; Kathmandu and Sarlahi District, Nepal
- China Stroke Primary Prevention Trial 2 for Participants With H-type Hypertension and MTHFR 677 CC/CT Genotype (CSPPT2-CC/CT)Pivotal-lookingRecruiting
Shenzhen Ausa Pharmed Co.,LtdIndustry
NCT04974138 · 32,000 participants (planned) · Start Aug 22, 2024 · Primary completion Jun 30, 2030
Drug: Amlodipine besylate; Amlodipine besylate and folic acid and 2 more · For: Hypertension; MTHFR 677 CC or CT Genotype; Elevated Plasma Homocysteine (Hcy≥10µmol/L) and 1 more
Sites: Bengbu, China; Bozhou, China; Chizhou, China · 20 sites in all
- China Stroke Primary Prevention Trial 2 for Participants With Hypertension and MTHFR 677 TT GenotypePivotal-lookingRecruiting
Shenzhen Ausa Pharmed Co.,LtdIndustry
NCT04974151 · 24,000 participants (planned) · Start Aug 22, 2024 · Primary completion Jun 30, 2029
Drug: Amlodipine besylate; Amlodipine besylate And Folic Acid and 4 more · For: Hypertension; MTHFR 677 TT Genotype
Sites: Bengbu, China; Bozhou, China; Chizhou, China · 20 sites in all
- China Stroke Primary Prevention TrialPivotal-lookingCompleted
Shenzhen Ausa Pharmed Co.,LtdIndustry
NCT00794885 · 20,702 participants · Start May 2008 · Primary completion Aug 2013
Drug: Enalapril/folic acid; Enalapril maleate · For: Primary Hypertension
Sites: Anqing, China; Lianyungang, China
- Folic Acid and Intensive Antihypertensive Therapy for Hypertension With CSVDPivotal-lookingNot yet recruiting
Beijing Tiantan HospitalAcademic, hospital or other
NCT05169021 · 15,000 participants (planned) · Start Dec 31, 2021 · Primary completion Dec 31, 2024
Drug: Amlodipine folic acid 5.8mg+intensive antihypertensive therapy; Amlodipine folic acid 5.8mg+standard antihypertensive therapy and 2 more · For: Cerebral Small Vessel Diseases; Stroke
Sites: Beijing, China
- Study of the Effectiveness of Additional Reductions in Cholesterol and HomocysteinePivotal-lookingCompleted
University of OxfordAcademic, hospital or other
NCT00124072 · 12,064 participants · Start Jul 1998 · Primary completion May 2008
Drug: Simvastatin 20 mg daily; Simvastatin 80 mg daily and 1 more · For: Cardiovascular Disease
Sites: Oxford, United Kingdom
- Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic LymphomaPivotal-lookingCompleted
Children's Oncology GroupResearch network
NCT01190930 · 9,350 participants · Start Aug 11, 2010 · Primary completion Mar 31, 2019
Drug: Cyclophosphamide; Cytarabine and 8 more · For: Acute Lymphoblastic Leukemia; Adult B Lymphoblastic Lymphoma; Ann Arbor Stage I B Lymphoblastic Lymphoma and 7 more
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 243 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective25,501
- fatigue24,215
- pain23,889
- arthralgia20,192
- off label use18,427
- rheumatoid arthritis18,093
- nausea16,256
- diarrhoea14,829
- headache14,796
- rash14,199
- dyspnoea13,866
- abdominal discomfort12,119
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 4,028 |
| 2005 | 3,947 |
| 2006 | 3,047 |
| 2007 | 3,025 |
| 2008 | 3,897 |
| 2009 | 5,191 |
| 2010 | 5,881 |
| 2011 | 7,320 |
| 2012 | 10,346 |
| 2013 | 11,131 |
| 2014 | 11,991 |
| 2015 | 14,840 |
| 2016 | 16,506 |
| 2017 | 14,724 |
| 2018 | 15,635 |
| 2019 | 16,226 |
| 2020 | 18,152 |
| 2021 | 16,635 |
| 2022 | 16,696 |
| 2023 | 14,171 |
| 2024 | 14,802 |
| 2025 | 13,764 |
| 2026 | 9,022 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Effects of Vitamin B12 Supplementation on Cognitive Function, Depressive Symptoms, and Fatigue: A Systematic Review, Meta-Analysis, and Meta-Regression.
Markun S, Gravestock I, Jäger L, et al. · Nutrients 2021 · Meta-Analysis, Systematic Review
- Folic acid supplementation for stroke prevention: A systematic review and meta-analysis of 21 randomized clinical trials worldwide.
Zhang N, Zhou Z, Chi X, et al. · Clin Nutr 2024 · Systematic Review, Meta-Analysis
- Effects of folic acid supplementation on cognitive impairment: A meta-analysis of randomized controlled trials.
Xu M, Zhu Y, Chen J, et al. · J Evid Based Med 2024 · Systematic Review, Meta-Analysis
- Effects of Vitamin D3 Combined with Folic Acid on Domain and Specific Cognitive Function among Patients with Mild Cognitive Impairment: A Randomized Clinical Trial.
Liu W, Zheng D, Li X, et al. · J Prev Alzheimers Dis 2024 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Micronutrient deficiencies in patients with celiac disease: A systematic review and meta-analysis.
Lamjadli S, Oujamaa I, Souli I, et al. · Int J Immunopathol Pharmacol 2025 · Systematic Review, Meta-Analysis
- Serum folic acid levels and erectile dysfunction: A meta-analysis and systematic review.
Xu J, Wang C, Zhang X, et al. · Andrologia 2021 · Meta-Analysis, Systematic Review
Sponsor: Solubiomix
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.